Potential nephroprotective effects of resveratrol in drug induced nephrotoxicity: a narrative review of safety and efficacy data

Al Dera HS (2016) Protective effect of resveratrol against aluminum chloride induced nephrotoxicity in rats. Saudi Med J 37(4):369. https://doi.org/10.15537/smj.2016.4.13611 Albertoni G, Schor N (2015) Resveratrol plays important role in protective mechanisms in renal disease-mini-review. J Bras Nefrol 37(1):106–114 Alexander JW, Metze TJ, McIntosh MJ, Goodman HR, First MR, Munda R, Safdar S (2005) The influence of immunomodulatory diets on transplant success and complications. Transplantation 79(4):460–465 Amudha G, Josephine A, Varalakshmi P (2006) Role of lipoic acid in reducing the oxidative stress induced by cyclosporine A. Clin Chim Acta 372(1–2):134–139 Ansari KA, Vavia PR, Trotta F, Cavalli R (2011) Cyclodextrin-based nanosponges for delivery of resveratrol: in vitro characterisation, stability, cytotoxicity and permeation study. AAPS Pharmscitech 12(1):279–286 Basavaraj S, Betageri GV (2014) Improved oral delivery of resveratrol using proliposomal formulation: investigation of various factors contributing to prolonged absorption of unmetabolized resveratrol. Exp Opin Drug Deliv 11(4):493–503 Benesic A, Schwerdt G, Hennemeier I, Sauvant C, Mildenberger S, Gekle M (2014) The nephrotoxic Ifosfamide-metabolite chloroacetaldehyde interferes with renal extracellular matrix homeostasis. Cell Physiol Biochem 33(4):1106–1116 Berman AY, Motechin RA, Wiesenfeld MY, Holz MK (2017) The therapeutic potential of resveratrol: a review of clinical trials. NPJ Precis Oncol 1(1):35 Bienholz A, Pang RM, Guberina H, Rauen U, Witzke O, Wilde B, Kribben A (2017) Resveratrol does not protect from ischemia-induced acute kidney injury in an in vivo rat model. Kidney Blood Press R 42(6):1090–1103 Bonechi C, Martini S, Ciani L, Lamponi S, Rebmann H, Rossi C, Ristori S (2012) Using liposomes as carriers for polyphenolic compounds: the case of trans-resveratrol. PLoS ONE 7(8):e41438. https://doi.org/10.1371/journal.pone.0041438 Bradamante S, Barenghi L, Villa A (2004) Cardiovascular protective effects of resveratrol. Cardiovasc Drug Rev 22(3):169–188 Brasnyó P, Molnár GA, Mohás M, Markó L, Laczy B, Cseh J, Halmai R (2011) Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr 106(3):383–389 Burdmann EA, Andoh TF, Yu L, Bennett WM (2003) Cyclosporine nephrotoxicity. Semin Nephrol 23(5):465–476 Cai S, Yang Q, Bagby TR, Forrest ML (2011) Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles. Adv Drug Deliv Rev 63(10–11):901–908 Carter LG, D'Orazio JA, Pearson KJ (2014) Resveratrol and cancer: focus on in vivo evidence. Endocr Relat Cancer 21(3):R209–R225. https://doi.org/10.1530/ERC-13-0171 Chander V, Chopra K (2005) Role of nitric oxide in resveratrol-induced renal protective effects of ischemic preconditioning. J Vasc Surg 42(6):1198–1205 Chander V, Chopra K (2006) Protective effect of nitric oxide pathway in resveratrol renal ischemia-reperfusion injury in rats. Arch Med Res 37(1):19–26 Chander V, Tirkey N, Chopra K (2005) Resveratrol, a polyphenolic phytoalexin protects against cyclosporine-induced nephrotoxicity through nitric oxide dependent mechanism. Toxicology 210(1):55–64 Chen JM, Bai JY, Yang KX (2018) Effect of resveratrol on doxorubicin resistance in breast neoplasm cells by modulating PI3K/Akt signaling pathway. IUBMB Life 70(6):491–500 Cid TP, Garcıa JC, Alvarez FC, De Arriba G (2003) Antioxidant nutrients protect against cyclosporine A nephrotoxicity. Toxicology 189(1–2):99–111 Clément M-V, Hirpara JL, Chawdhury S-H, Pervaiz S (1998) Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood 92(3):996–1002 Colombo M, Cassano N, Bellia G, Vena G (2013) Cyclosporine regimens in plaque psoriasis: an overview with special emphasis on dose, duration, and old and new treatment approaches. ScientificWorldJournal. https://doi.org/10.1155/2013/805705 Crowell JA, Korytko PJ, Morrissey RL, Booth TD, Levine BS (2004) Resveratrol-associated renal toxicity. Toxicol Sci 82(2):614–619 Darwish MA, Abo-Youssef AM, Khalaf MM, Abo-Saif AA, Saleh IG, Abdelghany TM (2018) Resveratrol influences platinum pharmacokinetics: a novel mechanism in protection against cisplatin-induced nephrotoxicity. Toxicol Lett 290:73–82 De Nicola L, Thomson SC, Wead LM, Brown MR, Gabbai FB (1993) Arginine feeding modifies cyclosporine nephrotoxicity in rats. J Clin Invest 92(4):1859–1865 Dera HA, Abushouk A (2015) Protective effect of resveratrol against aluminium chloride (AlCl3) induced testicular damage in rats entails inhibition of intrinsic apoptotic pathway. Sci Adv Mater 7(2):384–395 Do Amaral CL, Francescato HDC, Coimbra TM, Costa RS, Darin JDAC, Antunes LMG, Bianchi MDLP (2008) Resveratrol attenuates cisplatin-induced nephrotoxicity in rats. Arch Toxicol 82(6):363–370 Dubourg L, Michoudet C, Cochat P, Baverel G (2001) Human kidney tubules detoxify chloroacetaldehyde, a presumed nephrotoxic metabolite of ifosfamide. J Am Soc Nephrol 12(8):1615–1623 El-Kashef D, El-Kenawi A, Suddek G, Salem H (2017) Allicin ameliorates kidney function and urinary bladder sensitivity in cyclosporine A-treated rats. Hum Exp Toxicol 36(7):681–691 El-Shitany NA, El-Haggar S, El-Desoky K (2008) Silymarin prevents adriamycin-induced cardiotoxicity and nephrotoxicity in rats. Food Chem Toxicol 46(7):2422–2428 El-Sheikh AA, Morsy MA, Al-Taher AY (2016) Protective mechanisms of resveratrol against methotrexate-induced renal damage may involve BCRP/ABCG2. Fundam Clin Pharmacol 30(5):406–418 Galletti P, Di Gennaro CI, Migliardi V, Indaco S, Della Ragione F, Manna C, Zappia V (2005) Diverse effects of natural antioxidants on cyclosporin cytotoxicity in rat renal tubular cells. Nephrol Dial Transpl 20(8):1551–1558 Gambini J, Inglés M, Olaso G, Lopez-Grueso R, Bonet-Costa V, Gimeno-Mallench L, Vina J (2015) Properties of resveratrol: in vitro and in vivo studies about metabolism, bioavailability, and biological effects in animal models and humans. Oxid Med Cell Longev 2015:837042. https://doi.org/10.1155/2015/837042 Gan Y, Tao S, Cao D, Xie H, Zeng Q (2017) Protection of resveratrol on acute kidney injury in septic rats. Hum Exp Toxicol 36(10):1015–1022 Garvin S, Öllinger K, Dabrosin C (2006) Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett 231(1):113–122 Gehm BD, McAndrews JM, Chien P-Y, Jameson JL (1997) Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci 94(25):14138–14143 Gokce EH, Korkmaz E, Dellera E, Sandri G, Bonferoni MC, Ozer O (2012) Resveratrol-loaded solid lipid nanoparticles versus nanostructured lipid carriers: evaluation of antioxidant potential for dermal applications. Int J Nanomed 7:1841. https://doi.org/10.2147/IJN.S29710 Goldhahn K, Schmetterer K, Steiner G, Hintersteininger M, Erker T, Kloesch B (2015) A8. 20 A novel resveratrol prodrug: anti-proliferative and pro-apoptotic effects in human T-cells. Ann Rheum Dis 74(1):A89–A90. https://doi.org/10.1136/annrheumdis-2015-207259.205 Guo W, Li A, Jia Z, Yuan Y, Dai H, Li H (2013) Transferrin modified PEG-PLA-resveratrol conjugates: in vitro and in vivo studies for glioma. Eur J Pharmacol 718(1–3):41–47 Hao Q, Xiao X, Zhen J, Feng J, Song C, Jiang B, Hu Z (2016) Resveratrol attenuates acute kidney injury by inhibiting death receptor-mediated apoptotic pathways in a cisplatin-induced rat model. Mol Med Rep 14(4):3683–3689 Harde H, Das M, Jain S (2011) Solid lipid nanoparticles: an oral bioavailability enhancer vehicle. Exp Opin Drug Deliv 8(11):1407–1424 Holthoff JH, Wang Z, Seely KA, Gokden N, Mayeux PR (2012) Resveratrol improves renal microcirculation, protects the tubular epithelium, and prolongs survival in a mouse model of sepsis-induced acute kidney injury. Kidney Int 81(4):370–378 Hui Y, Lu M, Han Y, Zhou H, Liu W, Li L, Jin R (2017) Resveratrol improves mitochondrial function in the remnant kidney from 5/6 nephrectomized rats. Acta Histochem 119(4):392–399 Ibrahim A, Al-Hizab FA, Abushouk AI, Abdel-Daim MM (2018) Nephroprotective effects of benzyl isothiocyanate and resveratrol against cisplatin-induced oxidative stress and inflammation. Front Pharmacol. https://doi.org/10.3389/fphar.2018.01268 Jafari A, Dashti-Khavidaki S, Khalili H, Lessan-Pezeshki M (2013) Potential nephroprotective effects of l-carnitine against drug-induced nephropathy: a review of literature. Exp Opin Drug Saf 12(4):523–543 Jang I, Kim E, Lim J, Kim M, Ban T, Yoon H, Choi B (2018) Effects of resveratrol on the renin-angiotensin system in the aging kidney. Nutrients 10(11):1741 Kaloyanides GJ, Pastoriza-Munoz E (1980) Aminoglycoside nephrotoxicity. Kidney Int 18(5):571–582 Kane-Gill SL, Goldstein SL (2015) Drug-induced acute kidney injury: a focus on risk assessment for prevention. Crit Care Clin 31(4):675–684 Kane-Gill SL, Smithburger PL, Kashani K, Kellum JA, Frazee E (2017) Clinical relevance and predictive value of damage biomarkers of drug-induced kidney injury. Drug Saf 40(11):1049–1074 Kim DH, Jung YJ, Lee JE, Lee AS, Kang KP, Lee S, Ramkumar KM (2011) SIRT1 activation by resveratrol ameliorates cisplatin-induced renal injury through deacetylation of p53. Am J Physiol Ren Physiol 301(2):F427–F435 Kitada M, Koya D (2013) Renal protective effects of resveratrol. Oxid Med Cell Longev. https://doi.org/10.1155/2013/568093 Koda-Kimble MA (2012) Koda-Kimble and Young's applied therapeutics: the clinical use of drugs. Lippincott Williams & Wilkins, Philadelphia Kuypers DR, Neumayer HH, Fritsche L, Budde K, Rodicio JL, Vanrenterghem Y, Group LS (2004) Calcium channel blockade and preservation of renal graft function in cyclosporine-treated recipients: a prospective randomized placebo-controlled 2-year study. Transplantation 78(8):1204–1211 Launay-Vacher V, Rey J-B, Isnard-Bagnis C, Deray G, Daouphars M (2008) Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol 61(6):903–909 Lawenda BD, Kelly KM, Ladas EJ, Sagar SM, Vickers A, Blumberg JB (2008) Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? J Natl Cancer Inst 100(11):773–783 Lin C-T, Sun X-Y, Lin A-X (2016) Supplementation with high-dose trans-resveratrol improves ultrafiltration in peritoneal dialysis patients: a prospective, randomized, double-blind study. Ren Fail 38(2):214–221 Lin Y-F, Lee Y-H, Hsu Y-H, Chen Y-J, Lin Y-F, Cheng F-Y, Chiu H-W (2017) Resveratrol-loaded nanoparticles conjugated with kidney injury molecule-1 as a drug delivery system for potential use in chronic kidney disease. Nanomedicine 12(22):2741–2756 Liu F-C, Tsai H-I, Yu H-P (2015) Organ-protective effects of red wine extract, resveratrol, in oxidative stress-mediated reperfusion injury. Oxid Med Cell Longev. https://doi.org/10.1155/2015/568634 Liu S, Zhao M, Zhou Y, Wang C, Yuan Y, Li L, Lu Y (2019) Resveratrol exerts dose-dependent anti-fibrotic or pro-fibrotic effects in kidneys: a potential risk to individuals with impaired kidney function. Phytomedicine 57:223–235 Lorenz P, Roychowdhury S, Engelmann M, Wolf G, Horn TF (2003) Oxyresveratrol and resveratrol are potent antioxidants and free radical scavengers: effect on nitrosative and oxidative stress derived from microglial cells. Nitric Oxide 9(2):64–76 Lu Z, Cheng B, Hu Y, Zhang Y, Zou G (2009) Complexation of resveratrol with cyclodextrins: solubility and antioxidant activity. Food Chem 113(1):17–20 Luo C-J, Luo F, Bu Q-D, Jiang W, Zhang W, Liu X-M, Ma R-X (2019) Protective effects of resveratrol on acute kidney injury in rats with sepsis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. https://doi.org/10.5507/bp.2019.006 Mahmood WA, Mshimesh BAR, Khazaal FAK, Jasim SY, Mahmood AA (2018) Potential effects of resveratrol on obesity-related nephropathy in Iraqi obese women. J Pharm Sci Rev Res 10(5):999–1005 Mattarei A, Azzolini M, Carraro M, Sassi N, Zoratti M, Paradisi C, Biasutto L (2013) Acetal derivatives as prodrugs of resveratrol. Mol Pharm 10(7):2781–2792 Mattarei A, Azzolini M, La Spina M, Zoratti M, Paradisi C, Biasutto L (2015) Amino acid carbamates as prodrugs of resveratrol. Sci Rep 5:15216. https://doi.org/10.1038/srep15216 Meng X, Maliakal P, Lu H, Lee M-J, Yang CS (2004) Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J Agr Food Chem 52(4):935–942 Meng J, Guo F, Xu H, Liang W, Wang C, Yang X-D (2016) Combination therapy using co-encapsulated resveratrol and paclitaxel in liposomes for drug resistance reversal in breast cancer cells in vivo. Sci Rep 6:22390. https://doi.org/10.1038/srep22390 Miller RP, Tadagavadi RK, Ramesh G, Reeves WB (2010) Mechanisms of cisplatin nephrotoxicity. Toxins 2(11):2490–2518 Mingeot-Leclercq M-P, Tulkens PM (1999) Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother 43(5):1003–1012 Mokni M, Hamlaoui S, Kadri S, Limam F, Amri M, Marzouki L, Aouani E (2016) Grape seed and skin extract protects kidney from doxorubicin-induced oxidative injury. Pak J Pharm Sci 29(3):961–968 Montsko G, Nikfardjam MSP, Szabo Z, Boddi K, Lorand T, Ohmacht R, Mark L (2008) Determination of products derived from trans-resveratrol UV photoisomerisation by means of HPLC–APCI-MS. J Photochem Photobiol A Chem 196(1):44–50 Morales AI, Buitrago JM, Santiago JM, Fernández-Tagarro M, López-Novoa JM, Pérez-Barriocanal F (2002) Protective effect of trans-resveratrol on gentamicin-induced nephrotoxicity. Antioxid Redox Signal 4(6):893–898 Morales AI, Rodríguez-Barbero A, Vicente-Sánchez C, Mayoral P, López-Novoa JM, Pérez-Barriocanal F (2006) Resveratrol inhibits gentamicin-induced mesangial cell contraction. Life Sci 78(20):2373–2377 Moyano-Mendez JR, Fabbrocini G, De Stefano D, Mazzella C, Mayol L, Scognamiglio I, De Rosa G (2014) Enhanced antioxidant effect of trans-resveratrol: potential of binary systems with polyethylene glycol and cyclodextrin. Drug Dev Ind Pharm 40(10):1300–1307 Naesens M, Kuypers DR, Sarwal M (2009) Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 4(2):481–508 Narayanan NK, Nargi D, Randolph C, Narayanan BA (2009) Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int J Cancer 125(1):1–8 Nasiri-Toosi Z, Dashti-Khavidaki S, Khalili H, Lessan-Pezeshki M (2013) A review of the potential protective effects of pentoxifylline against drug-induced nephrotoxicity. Eur J Clin Pharmacol 69(5):1057–1073 Neves AR, Queiroz JF, Reis S (2016) Brain-targeted delivery of resveratrol using solid lipid nanoparticles functionalized with apolipoprotein E. J Nanobiotechnol 14(1):27 Nøhr-Meldgaard K, Ovsepian A, Ingmer H, Vestergaard M (2018) Resveratrol enhances the efficacy of aminoglycosides against Staphylococcus aureus. Int J Antimicrob Agents 52(3):390–396 Osman A-MM, Telity SA, Damanhouri ZA, Al-Harthy SE, Al-Kreathy HM, Ramadan WS, Kamel F (2015) Chemosensitizing and nephroprotective effect of resveratrol in cisplatin–treated animals. Cancer Cell Int 15(1):6 Pannu N, Nadim MK (2008) An overview of drug-induced acute kidney injury. Crit Care Med 36(4):S216–S223. https://doi.org/10.1097/CCM.0b013e318168e375 Patel KR, Scott E, Brown VA, Gescher AJ, Steward WP, Brown K (2011) Clinical trials of resveratrol. Ann N Y Acad Sci 1215(1):161–169 Popat R, Plesner T, Davies F, Cook G, Cook M, Elliott P, Cavenagh J (2013) A phase 2 study of SRT 501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma. Br J Haematol 160(5):714–717 Rauf A, Imran M, Butt MS, Nadeem M, Peters DG, Mubarak MS (2018) Resveratrol as an anti-cancer agent: A review. Crit Rev Food Sci Nutr 58(9):1428–1447 Saldanha JF, Leal VO, Rizzetto F, Grimmer GH, Ribeiro-Alves M, Daleprane JB, Mafra D (2016) Effects of resveratrol supplementation in Nrf2 and NF-κB expressions in nondialyzed chronic kidney disease patients: A randomized, double-blind, placebo-controlled, crossover clinical trial. J Ren Nutr 26(6):401–406 Şehirli Ö, Şakarcan A, Velioğlu-Öğünç A, Çetinel Ş, Gedik N, Yeğen BÇ, Şener G (2007) Resveratrol improves ifosfamide-induced Fanconi syndrome in rats. Toxicol Appl Pharmacol 222(1):33–41 Shahbazi F, Sadighi S, Dashti-Khavidaki S, Shahi F, Mirzania M, Abdollahi A, Ghahremani MH (2015) Effect of silymarin administration on cisplatin nephrotoxicity: report from a pilot, randomized, double-blinded, placebo-controlled clinical trial. Phytother Res 29(7):1046–1053 Siddalingappa B, Benson HA, Brown DH, Batty KT, Chen Y (2015) Stabilization of resveratrol in blood circulation by conjugation to mPEG and mPEG-PLA polymers: investigation of conjugate linker and polymer composition on stability, metabolism, antioxidant activity and pharmacokinetic profile. PLoS ONE 10(3):e0118824 Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22(47):7265. https://doi.org/10.1038/sj.onc.1206933 Silan C, Uzun Ö, Çomunoglu NÜ, Gokçen S, Bedirhan S, Cengiz M (2007) Gentamicin-induced nephrotoxicity in rats ameliorated and healing effects of resveratrol. Biol Pharm Bull 30(1):79–83 Singh CK, Ndiaye MA, Ahmad N (2015) Resveratrol and cancer: challenges for clinical translation. Biochim Biophys Acta 1852(6):1178–1185 Smoliga JM, Baur JA, Hausenblas HA (2011) Resveratrol and health—a comprehensive review of human clinical trials. Mol Nutr Food Res 55(8):1129–1141 Su J-Q, Wen Z, Wen Y-A, Xiao W-N, Lin J, Zheng Z-K (2016) Modification and stabilizing effects of PEG on resveratrol-loaded solid lipid nanoparticles. J Iran Chem Soc 13(5):881–890 Summerlin N, Soo E, Thakur S, Qu Z, Jambhrunkar S, Popat A (2015) Resveratrol nanoformulations: challenges and opportunities. Int J Pharm 479(2):282–290 Sun L-J, Sun Y-N, Chen S-J, Liu S, Jiang G-R (2017) Resveratrol attenuates skeletal muscle atrophy induced by chronic kidney disease via MuRF1 signaling pathway. Biochem Biophys Res Commun 487(1):83–89 Tacar O, Sriamornsak P, Dass CR (2013) Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol 65(2):157–170 Tatsioni A, Chung M, Sun Y, Kupelnick B, Lichtenstein AH, Perrone R, Bonis PA (2005) Effects of fish oil supplementation on kidney transplantation: a systematic review and meta-analysis of randomized, controlled trials. J Am Soc Nephrol 16(8):2462–2470 Turner RS, Thomas RG, Craft S, van Dyck CH, Mintzer J, Reynolds BA, Aisen PS (2015) A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology 85(16):1383–1391 Valentovic MA, Ball JG, Brown JM, Terneus MV, McQuade E, Van Meter S, Williams T (2014) Resveratrol attenuates cisplatin renal cortical cytotoxicity by modifying oxidative stress. Toxicol In Vitro 28(2):248–257 Vang O, Ahmad N, Baile CA, Baur JA, Brown K, Csiszar A, Lin H-Y (2011) What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS ONE 6(6):e19881. https://doi.org/10.1371/journal.pone.0019881 Varoni EM, Lo Faro AF, Sharifi-Rad J, Iriti M (2016) Anticancer molecular mechanisms of resveratrol. Front Nutr 3:8. https://doi.org/10.3389/fnut.2016.00008 Venkatesan N, Punithavathi D, Arumugam V (2000) Curcumin prevents adriamycin nephrotoxicity in rats. Br J Pharmacol 129(2):231–234 Vestergaard M, Ingmer H (2019) Antibacterial and antifungal properties of resveratrol. Int J Antimicrob Agents 53(6):716–723 Vijayakumar MR, Kumari L, Patel KK, Vuddanda PR, Vajanthri KY, Mahto SK, Singh S (2016) Intravenous administration of trans-resveratrol-loaded TPGS-coated solid lipid nanoparticles for prolonged systemic circulation, passive brain targeting and improved in vitro cytotoxicity against C6 glioma cell lines. RSC Adv 6(55):50336–50348 Walle T (2011) Bioavailability of resveratrol. Ann N Y Acad Sci 1215(1):9–15. https://doi.org/10.1111/j.1749-6632.2010.05842.x Wang Z-Y (2001) Arsenic compounds as anticancer agents. Cancer Chemother Pharmacol 48(1):S72–S76 Widemann BC, Adamson PC (2006) Understanding and managing methotrexate nephrotoxicity. Oncologist 11(6):694–703 Wiederrecht G, Lam E, Hung S, Martin M, Sigal N (1993) The mechanism of action of FK-506 and cyclosporin A. Ann N Y Acad Sci 696(1):9–19 Xia N, Strand S, Schlufter F, Siuda D, Reifenberg G, Kleinert H, Li H (2013) Role of SIRT1 and FOXO factors in eNOS transcriptional activation by resveratrol. Nitric Oxide 32:29–35 Xiao Z, Chen C, Meng T, Zhang W, Zhou Q (2016) Resveratrol attenuates renal injury and fibrosis by inhibiting transforming growth factor-β pathway on matrix metalloproteinase 7. Exp Biol Med 241(2):140–146 Xu S, Gao Y, Zhang Q, Wei S, Chen Z, Dai X, Zhao K-S (2016) SIRT1/3 activation by resveratrol attenuates acute kidney injury in a septic rat model. Oxid Med Cell Longev. https://doi.org/10.1155/2016/7296092 Xue H-Y, Yuan L, Cao Y-J, Fan Y-P, Chen X-L, Huang X-Z (2016) Resveratrol ameliorates renal injury in spontaneously hypertensive rats by inhibiting renal micro-inflammation. Biosci Rep. https://doi.org/10.1042/BSR20160035 Yu M, Xue J, Li Y, Zhang W, Ma D, Liu L, Zhang Z (2013) Resveratrol protects against arsenic trioxide-induced nephrotoxicity by facilitating arsenic metabolism and decreasing oxidative stress. Arch Toxicol 87(6):1025–1035 Zhang J, Tian Q, Zhou S-F (2006) Clinical pharmacology of cyclophosphamide and ifosfamide. Curr Drug Ther 1(1):55–84 Zhang W, Liu Y, Ge M, Jing J, Chen Y, Jiang H, Zhang Z (2014) Protective effect of resveratrol on arsenic trioxide-induced nephrotoxicity in rats. Nutr Res Pract 8(2):220–226 Zhu Y, Fu J, Shurlknight KL, Soroka DN, Hu Y, Chen X, Sang S (2015) Novel resveratrol-based aspirin prodrugs: synthesis, metabolism, and anticancer activity. J Med Chem 58(16):6494–6506